IMAC Holdings, Inc. Overview
Pro stress-test →IMAC Holdings operates through its subsidiary Ignite Proteomics, providing proteomic product and precision medicine services based on activated protein analysis for cancer treatment in the United States. The company offers a reverse phase protein array (RPPA) platform that quantifies protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development.
Strategic Profile
Pro stress-test →The company has announced research collaborations with academic institutions including Vanderbilt University Medical Center to advance immuno-oncology biomarker discovery. As a micro-cap OTC-traded biotech firm focused on protein analysis and cancer diagnostics, IMAC is positioned at the intersection of precision oncology and biomarker-driven treatment development.
Competitive Landscape
Pro stress-test →IMAC competes in the oncology diagnostics and biomarker discovery space against established players including Tempus AI, Foundation Medicine, and academic medical centers conducting similar proteomics research. However, the company lacks the scale, funding, and commercial infrastructure of these competitors.
Industry Context
IMAC Holdings, Inc. operates in Oncology diagnostics and precision medicine.
Key facts
Founded: 2000 · Headquarters: Brentwood, US · Employees: 15 · Revenue: N/A · Market cap: $217K